244 related articles for article (PubMed ID: 15701856)
21. Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas.
Farhadi MR; Capelle HH; Erber R; Ullrich A; Vajkoczy P
J Neurosurg; 2005 Feb; 102(2):363-70. PubMed ID: 15739567
[TBL] [Abstract][Full Text] [Related]
22. SU6668, a multitargeted angiogenesis inhibitor.
Hoekman K
Cancer J; 2001; 7 Suppl 3():S134-8. PubMed ID: 11779084
[TBL] [Abstract][Full Text] [Related]
23. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
Polverino A; Coxon A; Starnes C; Diaz Z; DeMelfi T; Wang L; Bready J; Estrada J; Cattley R; Kaufman S; Chen D; Gan Y; Kumar G; Meyer J; Neervannan S; Alva G; Talvenheimo J; Montestruque S; Tasker A; Patel V; Radinsky R; Kendall R
Cancer Res; 2006 Sep; 66(17):8715-21. PubMed ID: 16951187
[TBL] [Abstract][Full Text] [Related]
24. Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts.
Bockhorn M; Tsuzuki Y; Xu L; Frilling A; Broelsch CE; Fukumura D
Clin Cancer Res; 2003 Sep; 9(11):4221-6. PubMed ID: 14519649
[TBL] [Abstract][Full Text] [Related]
25. VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice.
Ou XM; Li WC; Liu DS; Li YP; Wen FQ; Feng YL; Zhang SF; Huang XY; Wang T; Wang K; Wang X; Chen L
Int Immunopharmacol; 2009 Jan; 9(1):70-9. PubMed ID: 18976720
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy.
Geng L; Donnelly E; McMahon G; Lin PC; Sierra-Rivera E; Oshinka H; Hallahan DE
Cancer Res; 2001 Mar; 61(6):2413-9. PubMed ID: 11289107
[TBL] [Abstract][Full Text] [Related]
27. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
Zhou Q; Olivo M; Lye KY; Moore S; Sharma A; Chowbay B
Cancer Chemother Pharmacol; 2005 Dec; 56(6):569-77. PubMed ID: 16001166
[TBL] [Abstract][Full Text] [Related]
28. [Effect of angiogenesis inhibitor SU6668 on the growth and metastasis of gastric cancer in SCID mice].
Jiang XT; Tao HQ; Zou SC
Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Jul; 9(4):335-7. PubMed ID: 16886118
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.
Kunkel P; Ulbricht U; Bohlen P; Brockmann MA; Fillbrandt R; Stavrou D; Westphal M; Lamszus K
Cancer Res; 2001 Sep; 61(18):6624-8. PubMed ID: 11559524
[TBL] [Abstract][Full Text] [Related]
30. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models.
Lee SH; Lopes de Menezes D; Vora J; Harris A; Ye H; Nordahl L; Garrett E; Samara E; Aukerman SL; Gelb AB; Heise C
Clin Cancer Res; 2005 May; 11(10):3633-41. PubMed ID: 15897558
[TBL] [Abstract][Full Text] [Related]
31. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.
Fong TA; Shawver LK; Sun L; Tang C; App H; Powell TJ; Kim YH; Schreck R; Wang X; Risau W; Ullrich A; Hirth KP; McMahon G
Cancer Res; 1999 Jan; 59(1):99-106. PubMed ID: 9892193
[TBL] [Abstract][Full Text] [Related]
32. The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.
Scholz A; Wagner K; Welzel M; Remlinger F; Wiedenmann B; Siemeister G; Rosewicz S; Detjen KM
Gut; 2009 Feb; 58(2):261-70. PubMed ID: 18829975
[TBL] [Abstract][Full Text] [Related]
33. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
34. AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice.
Park YW; Younes MN; Jasser SA; Yigitbasi OG; Zhou G; Bucana CD; Bekele BN; Myers JN
Clin Cancer Res; 2005 Mar; 11(5):1963-73. PubMed ID: 15756022
[TBL] [Abstract][Full Text] [Related]
35. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
Ning S; Laird D; Cherrington JM; Knox SJ
Radiat Res; 2002 Jan; 157(1):45-51. PubMed ID: 11754641
[TBL] [Abstract][Full Text] [Related]
36. A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability.
Patel N; Sun L; Moshinsky D; Chen H; Leahy KM; Le P; Moss KG; Wang X; Rice A; Tam D; Laird AD; Yu X; Zhang Q; Tang C; McMahon G; Howlett A
J Pharmacol Exp Ther; 2003 Sep; 306(3):838-45. PubMed ID: 12766257
[TBL] [Abstract][Full Text] [Related]
37. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions.
Laschke MW; Elitzsch A; Vollmar B; Vajkoczy P; Menger MD
Hum Reprod; 2006 Jan; 21(1):262-8. PubMed ID: 16172144
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
Giles FJ; Cooper MA; Silverman L; Karp JE; Lancet JE; Zangari M; Shami PJ; Khan KD; Hannah AL; Cherrington JM; Thomas DA; Garcia-Manero G; Albitar M; Kantarjian HM; Stopeck AT
Cancer; 2003 Apr; 97(8):1920-8. PubMed ID: 12673719
[TBL] [Abstract][Full Text] [Related]
39. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
[TBL] [Abstract][Full Text] [Related]
40. Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells.
Bischof M; Abdollahi A; Gong P; Stoffregen C; Lipson KE; Debus JU; Weber KJ; Huber PE
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1220-32. PubMed ID: 15519795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
